Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Welcome and Introduction to Vi3C

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Jun

Today In Oncology

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Welcome and Introduction to Vi3C

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy

HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors

Neoadjuvant Nivolumab and Chemotherapy Shows Significant OS Benefit at 5 Years in Resectable NSCLC

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Diagnostic Accuracy of Navigational Bronchoscopy vs Transthoracic Needle Biopsy in Lung Nodules